Humrich et al. used low-dose IL-2 to treat SLE with moderate-to-severe disease activity, supporting that Treg defects were associated with disease severity and could be corrected using low-dose IL-2, especially for active and refractory SLE [24]. Here, IL2 is linked to systemic lupus erythematosus.